Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jinhe Biotechnology Co. Ltd. (002688.SZ)
Dalian, CN
Founded in 1990 and headquartered in Dalian, China, Jinhe Biotechnology Co. Ltd. focuses on the development and distribution of animal health pharmaceuticals both domestically and internationally. The company provides chlortetracycline in a feed-grade formulation, an antimicrobial compound vital for preventing and treating conditions like white dysentery, enteritis, pneumonia, typhoid, paratyphoid, and cholera in poultry and livestock. Additionally, its offerings include chlortetracycline hydrochloride, utilized to combat pullorum disease, typhoid, swine enteritis, and other bacterial ailments such as paratyphoid and cholera. Jinhe Biotechnology extends its market reach globally, exporting these veterinary solutions to regions including the United States, Southeast Asia, Latin America, and Europe.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.23% | -2.99% | -8.31% | -12.24% | -10.53% | -7.23% | -13.07% | +7.18% | -21.03% | -38.80% | -10.10% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+21.4% ★ Q1'26: +18.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-72.9% Q1'26: +24.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2.0% Q1'26: -9.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.4% Q1'26: +13.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.1% Q1'26: +7.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.8% Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.77× Q1'26: 6.84× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.50B
est: 1.48B (+1.1%)
|
1.46B
est: 1.58B (-7.6%)
|
1.63B
est: 1.92B (-15.1%)
|
1.78B
est: 2.37B (-24.6%)
|
2.10B
est.
|
2.08B
est: 2.47B (-16.0%)
|
2.12B
est: 2.23B (-4.9%)
|
2.17B
est: 2.23B (-2.6%)
|
2.37B
est: 2.49B (-4.6%)
|
2.88B
est: 2.88B (-0.1%)
|
3.29B
3.29B – 3.29B
+14.2% YoY
|
| EBITDA |
298.02M
est: 215.88M (+38.1%)
|
259.71M
est: 230.14M (+12.8%)
|
333.70M
est: 279.94M (+19.2%)
|
383.81M
est: 344.97M (+11.3%)
|
306.58M
est.
|
327.73M
est: 360.76M (-9.2%)
|
307.35M
est: 325.71M (-5.6%)
|
334.54M
est: 325.71M (+2.7%)
|
276.99M
est: 347.92M (-20.4%)
|
364.19M
est: 403.05M (-9.6%)
|
460.27M
460.27M – 460.27M
+14.2% YoY
|
| EBIT |
241.78M
est: 105.80M (+128.5%)
|
187.29M
est: 112.79M (+66.0%)
|
247.37M
est: 137.20M (+80.3%)
|
284.36M
est: 169.08M (+68.2%)
|
150.26M
est.
|
196.76M
est: 176.81M (+11.3%)
|
158.17M
est: 159.63M (-0.9%)
|
161.67M
est: 159.63M (+1.3%)
|
91.80M
est: 161.99M (-43.3%)
|
125.25M
est: 187.66M (-33.3%)
|
214.30M
214.30M – 214.30M
+14.2% YoY
|
| Net Income |
164.13M
est: 201.33M (-18.5%)
|
108.42M
est: 251.66M (-56.9%)
|
163.63M
est: 387.17M (-57.7%)
|
184.94M
est: 487.84M (-62.1%)
|
309.74M
est.
|
93.99M
est: 410.40M (-77.1%)
|
75.62M
est: 147.13M (-48.6%)
|
86.46M
est: 147.13M (-41.2%)
|
100.20M
est: 140.52M (-28.7%)
|
27.56M
est: 257.61M (-89.3%)
|
382.52M
382.52M – 382.52M
+48.5% YoY
|
| SGA |
256.57M
est: 132.90M (+93.1%)
|
268.95M
est: 141.68M (+89.8%)
|
309.32M
est: 172.34M (+79.5%)
|
296.79M
est: 212.37M (+39.8%)
|
188.74M
est.
|
309.75M
est: 222.09M (+39.5%)
|
346.79M
est: 200.51M (+73.0%)
|
363.30M
est: 200.51M (+81.2%)
|
396.33M
est: 353.70M (+12.1%)
|
186.13M
est: 409.75M (-54.6%)
|
467.92M
467.92M – 467.92M
+14.2% YoY
|
| EPS |
0.26
est: 0.26 (+0.0%)
|
0.17
est: 0.33 (-47.7%)
|
0.26
est: 0.50 (-48.0%)
|
0.29
est: 0.63 (-54.0%)
|
0.40
est.
|
0.14
est: 0.53 (-73.6%)
|
0.10
est: 0.19 (-49.0%)
|
0.11
est: 0.19 (-42.1%)
|
0.13
est: 0.18 (-27.8%)
|
0.04
est: 0.33 (-89.3%)
|
0.49
0.49 – 0.49
+48.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changxian Xie | GM & Director | — | male |
| Lihang Zhou | Chief Accounting Officer | — | — |
| Manman Lu | Board Secretary & Director | — | male |
| Mingsheng Jian | Deputy General Manager | — | male |
| Ying Chun Liu | Deputy General Manager | — | male |
| Yingzhen Guan | Deputy General Manager | — | male |
| You Shan Niu | Financial Director | — | male |
| Yueqing Wang | Deputy GM & Non-Independent Director | — | female |
| Zhi Jun Wang | Deputy GM & Director | — | male |
| Zhi Sheng Wang | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002688.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
